The article paints a portrait of Maryland as a strategically positioned locus for advanced biopharmaceutical innovation, but its presentation subtly reinforces a narrative of ‘disruptive’ progress against persistent systemic challenges. The rapid succession of company activity – Regenxbio's regulatory stumbles alongside Faeth's acquisition and Sensei’s subsequent takeover – demonstrates a pattern of high-risk, high-reward ventures, aligning with ARC-0043 (Motte-and-Bailey) – a common tactic of p...